专利检索 ap:("IDORSIA PHARMACEUTICALS LTD") AND inv:"Mark Murphy" 第 1 页

1.

发明授权
C5A receptor modulators 有权

公开(公告)号：US11739070B2

公开(公告)日：2023-08-29

申请号：US16963101

申请日：2019-01-18

申请人： IDORSIA PHARMACEUTICALS LTD

发明人： Sylvie Froidevaux , Francis Hubler , Mark Murphy , Dorte Renneberg , Simon Stamm

IPC分类号： C07D401/04 , C07D401/14 , C07D403/04 , C07D405/14 , C07D413/14 , C07D471/04

CPC分类号： C07D401/04 , C07D401/14 , C07D403/04 , C07D405/14 , C07D413/14 , C07D471/04

摘要： The present invention relates to derivatives of formula (I)

wherein ring A, X, Y, Z, R1, R2, R3 and R4 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as C5a receptor modulators.

2.

发明授权
Substituted tetrahydropyrazolo[3,4-d]pyrimidines and tetrahydropyrazolo[4,3-d]pyrimidines as C5A receptor modulators 有权

公开(公告)号：US11608341B2

公开(公告)日：2023-03-21

申请号：US16961600

申请日：2019-01-09

申请人： Idorsia Pharmaceuticals Ltd.

发明人： Sylvie Froidevaux , Francis Hubler , Mark Murphy , Dorte Renneberg , Simon Stamm

IPC分类号： A61K31/519 , C07D487/04

摘要： The present invention relates to derivatives of formula (I) wherein Ring A, X, Y, Z, RA, R1, R2, R3 and R4 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as C5a receptor modulators.

3.

发明授权
C5a receptor modulators 有权

公开(公告)号：US11685729B2

公开(公告)日：2023-06-27

申请号：US16963143

申请日：2019-01-18

申请人： IDORSIA PHARMACEUTICALS LTD.

发明人： Sylvie Froidevaux , Francis Hubler , Mark Murphy , Dorte Renneberg , Simon Stamm

IPC分类号： C07D401/04 , C07D403/04 , C07D401/14 , C07D417/14 , C07D487/04

CPC分类号： C07D403/04 , C07D401/04 , C07D401/14 , C07D417/14 , C07D487/04

摘要： The present invention relates to derivatives of formula (I)

wherein Ring A, W, X, Y, Z, R1, R2, R3 and R4 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as C5a receptor modulators.